TVTX Q3 2018 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+0.9% YoY

Gross Profit

$40M97.2% margin

Operating Income

-$36M-87.4% margin

Net Income

-$55M-133.9% margin

EPS (Diluted)

$-1.34

QoQ Revenue Growth

-1.5%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$8M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$716M

Total Liabilities

$397M

Stockholders' Equity

$319M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$40M	+0.9%
Gross Profit	$40M	$39M	+0.4%
Operating Income	-$36M	-$11M	-235.4%
Net Income	-$55M	-$18M	-206.4%

Revenue Segments

Thiola License

$23M56%

Bile Acid Products

$18M44%